Clinical trials
Other Cancer clinical trials
Below are recruiting other cancer clinical trials, each written for real people, not researchers. We’re tracking 13,144 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07061951RecruitingPhase 2
Mirdametinib for relapsed or refractory CLL or SLL
This trial tests a drug called mirdametinib for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to at least two prior treatments, including a BTK inhibitor and a BCL2 inhibitor. The goal is to see if mirdametinib can help shrink the cancer or slow its growth.
Duarte, CaliforniaAges 18 years+ - NCT07062549RecruitingPhase 1
New imaging agent for metastatic clear cell kidney cancer
This trial tests a new radioactive imaging agent (111In-XYIMSR-01) to see how well it finds clear cell kidney cancer that has spread. It involves a special SPECT/CT scan and may help doctors better see where the cancer is.
Baltimore, MarylandAges 18 years+ - NCT07062965RecruitingPhase 3
PF-07248144 with fulvestrant for HR+ HER2- advanced breast cancer
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
Chandler, ArizonaAges 18 years+ - NCT07065435RecruitingPhase 2
RC48 with Avastin or Pyrotinib for HER2+ breast cancer after T-DXd
This trial tests a new combination of drugs (RC48 plus either Avastin or Pyrotinib) for people with HER2-positive breast cancer that has spread and has stopped responding to the drug T-DXd. The goal is to see if these combinations can help shrink tumors and control the cancer longer.
Nanjing, JiangsuAges 18–75 - NCT07065630RecruitingPhase 2
New immunotherapy for HPV-negative head and neck cancer
This trial tests a new immunotherapy drug called volrustomig for people with advanced head and neck cancer that is not caused by HPV. The goal is to see if giving this treatment based on how the cancer responds can help shrink tumors or stop them from growing.
Chicago, IllinoisAges 18 years+ - NCT07066098RecruitingPhase 3
New drug IBI343 for advanced pancreatic cancer with CLDN18.2 protein
This study tests a new drug called IBI343 compared to a placebo (inactive substance) for people with advanced pancreatic cancer that has a specific protein (CLDN18.2) and has not responded to earlier treatments. The goal is to see if IBI343 can help slow the cancer's growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07066280RecruitingPhase 3
A cream to prevent skin irritation from radiation for breast cancer
This study tests a special cream that may prevent skin irritation (radiation dermatitis) caused by radiation therapy for breast cancer. The cream is made from natural weak acids and aims to protect the skin by keeping the skin's microbiome healthy.
Guangzhou, GuangdongAges 18–70 - NCT07066917Recruiting
Breast cancer treatment response study
This study looks at how well newer treatments work for advanced or metastatic breast cancer and why some people respond better than others. It is for anyone with HR-positive, HER2-positive/low, or triple-negative breast cancer who has started at least one treatment cycle.
AthensAges 18 years+ - NCT07067385RecruitingPhase 1
Personalized mRNA vaccine for advanced GI cancers
This trial tests a personalized mRNA vaccine designed to teach your immune system to attack your specific tumor. It is for people with advanced gastrointestinal cancers who have exhausted other options.
Shanghai, SHAges 18 years+ - NCT07068529Recruiting
Metabolic biomarkers for early diagnosis and recurrence of colorectal cancer
This study looks at metabolic biomarkers in blood and tumor tissue to help detect colorectal cancer earlier, predict outcomes, and monitor for recurrence. It includes both people newly diagnosed with colorectal cancer and healthy volunteers for comparison.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07068542Recruiting
New drug combo for advanced thyroid cancer
This trial tests a new drug called sacituzumab tirumotecan combined with immunotherapy for people with advanced thyroid cancer that cannot be removed by surgery or has spread. It aims to see if this combination can help shrink tumors or slow down the cancer.
Hangzhou, ZhejiangAges 18 years+ - NCT07068763RecruitingPhase 2
Short radiation plus drugs for early rectal cancer
This trial tests a combination of short-course radiation, chemotherapy (capecitabine), and two immunotherapy drugs (PD-1 and CTLA-4 inhibitors) for people with early-stage rectal cancer who want to avoid surgery and keep their anus. The goal is to see if this treatment can shrink the tumor enough to avoid major surgery.
Hangzhou, ZhejiangAges 18–80 - NCT07068711Recruiting
Nutritional health study for head and neck cancer patients
This study looks at the nutritional status of people with head and neck cancer who are receiving radiation therapy. The goal is to understand how their nutrition changes during treatment.
Istanbul, PendikAges 18 years+ - NCT07069335RecruitingPhase 1
Studying a new form of olaparib for BRCA-mutated ovarian cancer
This study tests a new form of a drug similar to olaparib (Lynparza) in people with BRCA-mutated ovarian cancer. It looks at how the drug works in the body and checks for safety, to see if the new formulation is as effective and safe as the current one.
Seoul, Songpa DistrictAges 19–74 - NCT07069842Recruiting
Gastric cancer immunotherapy prediction model
This study looks at markers in your tumor to predict how well immunotherapy might work for you. It aims to create a model that helps doctors choose the best treatment for advanced gastric cancer.
Changzhi, ShanxiAges 18–75 - NCT07070011Recruiting
Studying tiny particles in blood to predict treatment response in lung cancer
This trial looks at small particles called extracellular vesicles in your blood to see if they can help predict how well immunotherapy combined with chemotherapy will work for extensive-stage small cell lung cancer. The goal is to find markers that could guide future treatment decisions.
ShanghaiAges 45–80 - NCT07070622RecruitingPhase 3
Organ preservation for low rectal cancer after chemo
This trial tests whether chemotherapy alone can help avoid surgery for low rectal cancer. It is for people with tumors close to the anus that haven't spread far, and who haven't had prior cancer treatment.
Chengdu, SichuanAges 18–80 - NCT07070778Recruiting
Arterial stiffness study for breast cancer survivors
This study looks at how breast cancer treatment affects artery health. It tests whether artery stiffness is linked to recovery, and may help guide future rehabilitation programs.
Ankara, StateAges 40–69 - NCT07070791Recruiting
Exercise program for arm strength and fitness after breast cancer
This trial tests whether a combination of arm-strengthening and aerobic exercises helps breast cancer patients who are at least 15 months past surgery and not very active. The goal is to see if this home-based program improves arm function and overall fitness.
Ankara, StateAges 18–80 - NCT07071272Recruiting
Comparing two breast imaging methods before surgery
This trial compares a special mammogram with dye (CEDM) to MRI for women already diagnosed with invasive breast cancer. The goal is to see if CEDM works as well as MRI for planning surgery, potentially offering a faster or easier option.
Verona, ItalyAges 30 years+ - NCT07071337RecruitingPhase 3
Study of SKB264 vs chemo for HR+/HER2- breast cancer after hormone therapy
This trial tests a new drug, SKB264, against standard chemotherapy for people with a common type of breast cancer (HR+/HER2-) that has spread and stopped responding to hormone therapy. It may offer a new option if you haven't had chemotherapy for advanced disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT07071987Recruiting
Acupuncture for bowel recovery after colon cancer surgery
This trial tests if thread embedding acupuncture can help your bowels start working again faster after surgery for colorectal cancer. It may reduce discomfort and speed up recovery.
Yangzhou, JiangsuAges 18–80 - NCT07072377Recruiting
Nutrition counseling before cancer treatment starts
This trial tests whether a virtual nutrition consultation before starting cancer treatment can improve outcomes. If you have a solid tumor (not certain types) and are about to begin chemotherapy, immunotherapy, targeted therapy, or hormone therapy, this study may help you get personalized dietary advice from home.
Burlington, VermontAges 18 years+ - NCT07075679Recruiting
AI vs double reading for breast cancer screening
This study compares a single radiologist reading your mammogram with help from artificial intelligence (AI) to the standard method of two radiologists reading it. The goal is to see if AI-assisted reading is just as good at finding cancer while saving time and resources.
OlomoucAges 45–69
Hear when a new Other Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for other cancer?
- Yes. Clin2 currently lists 13,144 recruiting other cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a other cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a other cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.